Intrinsiqq
Atea Pharmaceuticals Inc. logo

Atea Pharmaceuticals Inc. Quality Score

AVIR

Compare
Quality40

Valuation is the primary weakness (avg 0/100). No single area scores well.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-2.0x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-2.3x

Negative FCF, no valuation support

Revenue Growth
100/100
622.5%

Above 10% CAGR, strong compounder

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
271.5%

Heavy dilution above 5%

Margin Trend
100/100
+62.1pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$191M

Net cash position, no leverage concern

2020
$850M
$0.00
2021
$764M
$197000
TTM
$191M
$213000
CashDebt
Return on Capital
0/100
-61.0%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Atea Pharmaceuticals (AVIR) quality: score, margins and returns

Atea Pharmaceuticals (AVIR) scores 40/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 6 metrics each scored 0 to 100 and -61.0% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Atea Pharmaceuticals (AVIR) a high-quality business?+

Atea Pharmaceuticals scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a -61.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Atea Pharmaceuticals's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from AVIR's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Atea Pharmaceuticals scores well and where it falls behind.

What is Atea Pharmaceuticals's return on invested capital (ROIC)?+

Atea Pharmaceuticals earns about -61.0% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to AVIR's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 6 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 9 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AVIR

CompareIntrinsic value
XERSXeris Biopharma Holdings, Inc.
$16.97+2.11%34
EOLSEvolus Inc.
$6.52-6.86%30
AUPHAurinia Pharmaceuticals Inc.
$14.70-1.28%58
IRWDIronwood Pharmaceuticals Inc.
$4.70-0.21%63
MNKDMannKind Corporation
$3.85-2.53%30
HROWHarrow Inc.
$30.41-5.35%15
SNDXSyndax Pharmaceuticals Inc.
$8.72-4.49%0
ESPREsperion Therapeutics Inc.
No recent price50

Held by ETFs

AVIR is in 13 US ETFs. The largest of them, with AVIR's weight in each:

Spot a number that looks wrong? Check it in AVIR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing AVIR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.